Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. operates commercially as Helus Pharma and reports developments as a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists for depression, anxiety, and other mental health conditions. Company updates commonly address HLP003 in major depressive disorder, HLP004 in generalized anxiety disorder, investigational 5-HT receptor-focused compounds, clinical-research collaborations, regulatory-policy commentary, and scientific or medical leadership additions.
News about the company also covers public-company finance and corporate structure, including common-share offerings, pre-funded warrants, at-the-market equity programs, exchange-listing changes, conference presentations, quarterly financial results, and governance transitions tied to its development-stage pharmaceutical operations.
Cybin, a biotechnology company focused on psychedelic therapeutics, has announced a new partnership with Catalent, the leader in drug delivery technologies. The agreement allows Cybin to utilize Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for its novel drug CYB003, aimed at treating resistant psychiatric disorders. This innovative delivery method promises improved pharmacokinetics by enabling pre-gastric absorption. The project begins in April 2021 with feasibility studies on various ODT formulations.
Cybin has successfully completed its 20th pre-clinical study and is advancing the proprietary psychedelic molecules CYB003 and CYB004 into Investigational New Drug (IND)-enabling studies. The studies utilized Cybin's technology and were executed rapidly through collaboration with partners. The company has initiated an API manufacturing contract and aims to address serious psychiatric conditions with these new candidates. Cybin boasts a discovery pipeline of over 50 proprietary psychedelic molecules, enhancing its position in the emerging psychedelic therapeutics market.
Cybin, a biotechnology company specializing in psychedelic therapeutics, announced that CEO Doug Drysdale will present a business and pipeline update at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 11:20 AM Eastern Time. The presentation will also be available via a live webcast for seven days afterward. Cybin is known for its innovative approaches to drug discovery, delivery systems, and psychiatric disorder treatments.
Cybin Inc. (NEO:CYBN, OTCQB:CLXPF), a biotechnology company focused on psychedelic therapeutics, announced that CEO Doug Drysdale will present a business update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference on March 17, 2021, at 3:30 PM ET. He will also participate in a panel discussion on psychedelics, which will be webcast live and available for replay for one week. Cybin leverages proprietary drug discovery and delivery systems to develop treatments for psychiatric disorders.
Cybin Inc. has commenced trading on the OTCQB under the symbol ‘CLXPF’ as of March 8, 2021. This move enhances the company's visibility and liquidity, allowing better access to both institutional and retail investors, as highlighted by CEO Doug Drysdale. The OTCQB, recognized by the SEC, offers stricter compliance and quality standards, which could positively impact investor confidence. Cybin continues to trade on the NEO Exchange under the symbol ‘CYBN’ and focuses on developing psychedelic therapeutics for mental health issues.